Combination therapy for advanced stomach cancer after prior treatments
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach cancer (stage IV) that has spread to other parts of the body.
- You have already tried at least two different cancer treatments.
- You are at least 18 years old.
- You are able to do most daily activities on your own (ECOG score 0-2).
- Your blood counts and organ function (kidney, liver) are within a certain range.
- You do not have serious heart, lung, or autoimmune conditions, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a new combination of drugs for advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
This trial tests a new combination of medications (IBI363 plus bevacizumab, with or without nab-paclitaxel) for people with advanced stomach cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth better than existing options.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after immunotherapy. The goal is to see if this combination helps control the cancer longer.
Hear when a new Gastric Cancer Adenocarcinoma Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.